Understanding the chemical foundation of pharmaceutical compounds is paramount, and Abiraterone Acetate (CAS 154229-18-2) is no exception. NINGBO INNO PHARMCHEM CO.,LTD. is dedicated to providing insights into the compounds we supply, highlighting the essential Abiraterone Acetate chemical properties that make it so significant in the pharmaceutical industry. Primarily recognized as a steroid antiandrogen for prostate cancer, its synthesis and molecular characteristics are key to its therapeutic action.

The molecular formula for Abiraterone Acetate is C26H33NO2, with a molecular weight of approximately 391.55. This complex steroidal structure is what enables it to act as a potent inhibitor of CYP17A1, thereby controlling androgen synthesis. As a critical Abiraterone Acetate pharmaceutical intermediate, its purity and structural integrity are rigorously maintained throughout the manufacturing process.

When pharmaceutical companies decide to buy Abiraterone Acetate API, they are investing in a compound that has undergone extensive research and development. The detailed understanding of its Abiraterone Acetate chemical properties allows for precise formulation and application, ensuring optimal patient outcomes. The stability and reactivity profile of this compound are carefully managed to ensure its efficacy when used in drug manufacturing.

The role of Abiraterone Acetate as a steroid antiandrogen for prostate cancer treatment is well-established. Its unique chemical makeup allows it to target specific biological pathways, making it a valuable asset in the fight against advanced stages of this disease. The consistent availability of this compound, with its specific Abiraterone Acetate CAS 154229-18-2, is a critical factor for ongoing clinical research and widespread therapeutic use.

At NINGBO INNO PHARMCHEM CO.,LTD., we are proud to support the pharmaceutical industry by supplying high-grade Abiraterone Acetate. Our focus on chemical precision ensures that our clients receive a product that meets the highest standards for their therapeutic innovations.